Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma

医学 肝细胞癌 内科学 外科肿瘤学 胃肠病学 养生 肿瘤科 肝癌 不利影响
作者
Changlong Hou,Baizhu Xiong,Lei Zhou,Yipeng Fei,Changgao Shi,Xianhai Zhu,Tao Xie,Yulin Wu
出处
期刊:BMC Cancer [BioMed Central]
卷期号:24 (1): 387-387 被引量:2
标识
DOI:10.1186/s12885-024-12144-6
摘要

Abstract Background The safety and efficacy of transarterial chemoembolization plus molecular targeted therapy (MTT) combined with immune checkpoint inhibitors (ICIs) in primary liver cancer have been demonstrated. However, the evidence for TACE plus MTT combined with ICIs in the treatment of recurrent hepatocellular carcinoma (RHCC) is limited. Given the excellent performance of this combination regimen in primary liver cancer, it is necessary to evaluate the efficacy of TACE plus MTT combined with ICIs in RHCC. Methods A total of 88 patients with RHCC treated with TACE plus MTT combined with camrelizumab (TACE-TC group, n = 46) or TACE plus MTT (TACE-T group, n = 42) were retrospectively collected and analyzed. In this study, we evaluated the effectiveness and safety of combination therapy for patients with RHCC by analyzing tumor response, progression-free survival (PFS), overall survival (OS), laboratory biochemical indices, and adverse events (AEs). Results TACE-TC was superior to TACE-T in PFS (14.0 vs. 8.9 months, p = 0.034) and OS (31.1 vs. 20.2 months, p = 0.009). Moreover, TACE-TC achieved more preferable benefits with respect to disease control rate (89.1% vs. 71.4%, p = 0.036) and objective response rate (47.8% vs. 26.2%, p = 0.036) compared with TACE-T in patients with RHCC. Compared with the TACE-T group, the AFP level in the TACE-TC group decreased more significantly after 3 months of treatment. Multivariate analysis showed that treatment option was a significant predictor of OS and PFS, while the portal vein tumor thrombus and interval of recurrence from initial treatment were another prognostic factor of PFS. There was no significant difference between the TACE-TC and TACE-T groups for Grade 3–4 adverse events. Conclusions A combination therapy of TACE, MTT, and camrelizumab significantly improved tumor response and prolonged survival duration, showing a better survival prognosis for RHCC patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zzz完成签到,获得积分10
刚刚
谨慎妙菡发布了新的文献求助10
1秒前
可爱的函函的应助被黄鑫采纳,获得10
1秒前
Ace发布了新的文献求助10
1秒前
zhujiaja发布了新的文献求助10
1秒前
葫芦侠发布了新的文献求助10
1秒前
GGbond发布了新的文献求助10
1秒前
神勇的寒香完成签到,获得积分10
1秒前
1秒前
2秒前
xu完成签到,获得积分10
2秒前
2秒前
钉钉发布了新的文献求助10
3秒前
3秒前
情怀的应助被怡然的海瑶采纳,获得10
3秒前
3秒前
小包完成签到,获得积分10
4秒前
cdercder的应助被个性的西瓜采纳,获得10
4秒前
4秒前
Min发布了新的文献求助50
4秒前
PC关闭了PC的文献求助
4秒前
阿萌毛毛发布了新的文献求助10
5秒前
5秒前
area完成签到,获得积分10
5秒前
Verna发布了新的文献求助10
6秒前
6秒前
二毛完成签到,获得积分0
6秒前
6秒前
虎王发布了新的文献求助10
6秒前
孙同学发布了新的文献求助10
6秒前
6秒前
Owen的应助被小马过河采纳,获得10
6秒前
7秒前
7秒前
7秒前
GGbond完成签到,获得积分10
7秒前
7秒前
合适的银耳汤完成签到,获得积分10
8秒前
斯文乐荷发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162138
求助须知:如何正确求助?哪些是违规求助? 9556501
关于积分的说明 21735379
捐赠科研通 7752349
什么是DOI,文献DOI怎么找? 3427639
关于科研通互助平台的介绍 2552678
邀请新用户注册赠送积分活动 2472242